Become a strategic partner for the industrialisation and commercialisation
of this innovation through an operating licence.
GYRO
Gene therapy for retinal dystrophies
Investment: 100k€
Scope: Health
Scientific field(s): Biology and Medicinal Chemistry
Institution(s): Université Paris-Saclay - CNRS
Development: Technology to be marketed
#1
Agnostic gene therapy for all retinal degenerative diseases
#2
Long-lasting neuroprotective effect demonstrated in preclinical trials
#3
Mature technology with high scientific credibility
USE CASES
- Agnostic product that can be applied to all retinal degenerative diseases.
- The first applications are photoreceptor degenerative diseases, Age-related macular diseases (AMD), Glaucoma.
APPLICATIONS
- A retinal neuroprotective protein has been discovered by the project team, based on their years of research on the underlying mechanism of action
- A gene therapy product can efficiently induce a long-term neuroprotective effect
ADVANTAGES
- Efficient neuroprotection
- Long-term therapeutic effect with AAVs
- Wide applications in retinal degenerative diseases
- Safety in the therapeutic area
- Expertise of the team in the domain